It is pretty much a cliché that the future of oncology lies in combination treatments, albeit a cliché with a lot of truth to it. Combinations, though, bring their own challenges. In many cases, efficacy and toxicity increase in lockstep, and in the context of clinical trial design, "endless possibilities" is a bug, not a feature.